论文部分内容阅读
高尔基体磷酸化蛋白(Golgi phosphoprotein 2,GOLPH2又称GP73)是一种II型高尔基体跨膜糖蛋白,与肝炎、肝硬化和肝癌等的发生发展密切相关。GP73是一个可靠的诊断HCC及监测复发的血清标记物,其敏感性和特异性均高于传统的AFP。GP73在目前的肝癌早期诊断和治疗中的显示出重要的作用,有可能成为临床上新的肝癌血清标记物。而且部分研究发现GP73对肝癌的转移潜能和预后有重要的预测价值,抑制其表达可显著降低肝癌细胞的恶性表型,这似乎提示GP73可以成为肝癌治疗的新靶点。
Golgi phosphoprotein 2 (GOLPH2, also known as GP73) is a type II Golgi transmembrane glycoprotein, which is closely related to the occurrence and development of hepatitis, cirrhosis and liver cancer. GP73 is a reliable serum marker for the diagnosis of HCC and monitoring of relapse with higher sensitivity and specificity than traditional AFP. GP73 in the early diagnosis and treatment of liver cancer has shown an important role in the clinical may become a new liver cancer serum markers. And some studies found that GP73 has an important predictive value for the metastatic potential and prognosis of HCC. Suppressing the expression of GP73 can significantly reduce the malignant phenotype of HCC cells, which seems to suggest that GP73 can be a new target for the treatment of HCC.